Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

References

• Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar
• Svendsen P, Shekhrajka N, Nielsen KL, et al. R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. Leuk Lymphoma. 2017;58(5):1105–1113.
   PubMed Web of Science ®Google Scholar
• Greenstein S, Ghias K, Krett NL, et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res. 2002;8(6):1681–1694.
   PubMed Web of Science ®Google Scholar
• Van Ryckeghem F. Corticosteroids, the oldest agent in the prevention of chemotherapy-induced nausea and vomiting: what about the guidelines? J Transl Int Med. 2016;4(1):46–51.
   PubMed Web of Science ®Google Scholar
• Svedbom A, Borgstom F, Hernlund E, et al. Quality of life for up to 18 months after low-energy hip, vertebral, and distal forearm fractures-results from the ICUROS. Osteoporos Int. 2018;29(3):557–566.
   PubMed Web of Science ®Google Scholar
• Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl. 5):v116–v125.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl. 5):v83–v90.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. B-cell Lymphomas (version 2.2019); 2019; [cited 2019 Apr 25]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
   Google Scholar
• Castellino A, Santambrogio E, Nicolosi M, et al. Follicular lymphoma: the management of elderly patient. Mediterr J Hematol Infect Dis. 2016;9(1):e2017009.
   Google Scholar
• Baech J, Hansen SM, Lund PE, et al. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish Nationwide Cohort Study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018;183(5):717–726.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121–3127.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Habermann TM, Shi Q, et al. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018;29(8):1822–1827.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Bogsted M, Brown PN, et al. Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish Population-Based Study. J Clin Oncol. 2017;35(7):778–784.
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood. 2017;130(Suppl. 1):486–486.
   Google Scholar
• Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2018;36(7):689–696.
   PubMed Web of Science ®Google Scholar
• Maurer MJ, Bachy E, Ghesquieres H, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016;91(11):1096–1101.
   PubMed Web of Science ®Google Scholar
• Arboe B, El-Galaly TC, Clausen MR, et al. The Danish National Lymphoma Registry: coverage and data quality. PLOS One. 2016;11(6):e0157999.
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39(7 Suppl.):38–41.
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39(7 Suppl.):30–33.
   PubMed Web of Science ®Google Scholar
• Martinussen T, Scheike TH. Dynamic regression models for survival data. 1st ed. New York: Springer-Verlag; 2006.
   Google Scholar
• SAS Institute Inc. SAS 9.4 (software). Cary (NC); 2013.
   Google Scholar
• Team RC. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. Available from: http://www.R-project.org/. 2013
   Google Scholar
• Seibel MJ, Cooper MS, Zhou H. Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol. 2013;1(1):59–70.
   PubMed Web of Science ®Google Scholar
• LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8(1):39–51.
   PubMedGoogle Scholar
• Brown JE, Ellis SP, Silcocks P, et al. Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res. 2006;12(21):6480–6486.
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18(7):1570–1593.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397.
   PubMed Web of Science ®Google Scholar
• Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J Bone Miner Res. 2014;29(3):518–530.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HGM, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
   PubMed Web of Science ®Google Scholar
• Westin JR, Thompson MA, Cataldo VD, et al. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial. Clin Lymphoma Myeloma Leuk. 2013;13(2):99–105.
   PubMed Web of Science ®Google Scholar